Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 5/20 | 0.31 |
| ▸ | EGFR | P00533 | 7/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | PRKDC | P78527 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887443 | 1.00 | STK4 (0.32) | STK4FAAHKCNJ1EGFRERBB2 | |
| SCHEMBL3882691 | 1.00 | STK4 (0.32) | STK4FAAHKCNJ1EGFRERBB2 | |
| SCHEMBL3882246 | 0.87 | MAP4K1 (0.35) | STK4EGFRERBB2PRKDC | |
| SCHEMBL3883355 | 0.84 | SRC (0.33) | EGFRERBB2 | |
| SCHEMBL3882728 | 0.83 | MAP3K8 (0.38) | STK4EGFRERBB2KCNH2 | |
| SCHEMBL5508752 | 0.82 | SRC (0.33) | — | |
| SCHEMBL3881126 | 0.82 | SRC (0.33) | — | |
| SCHEMBL3886273 | 0.81 | MELK (0.33) | EGFR | |
| SCHEMBL3882415 | 0.81 | SRC (0.33) | — | |
| SCHEMBL3880236 | 0.81 | EGFR (0.47) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | claimed |
| EP-1771443-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | claimed |
| WO-2006002828-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | claimed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | claimed |
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1771443-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006002828-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | STK4 133/4885FAAH 4778/4885KCNJ1 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.